OR WAIT null SECS
Growth and Advancements in Fill/Finish
Employing novel technologies and more patient-centric approaches
Delving into Biopharmaceutical Development and Manufacturing
Quality Considerations in Changing Excipient Providers
May 30, 2024
Lilly’s investment increase is intended to boost manufacturing capacity at its Lebanon, Ind., site for APIs used in the production of tirzepatide and other pipeline drug candidates.
A combination of rapid sterility methods with the industry standard compendial method should ensure maximum safety.
The company’s new division will provide end-to-end integrated discovery services.
At a recent INTERPHEX conference, Laura Moody (Director of Product Management, Pharma North America, Syntegon) shared some insights into current trends in the pharmaceutical industry, including the EU Annex 1.
FDA granted priority review to Sanofi's sBLA for Sarclisa in combination with VRd in treating transplant-ineligible patients who are newly diagnosed with multiple myeloma.
Bkemv (eculizumab-aeeb) is the first interchangeable biosimilar to Soliris (eculizumab) to treat paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Johnson & Johnson will gain NM26, a bispecific antibody targeting atopic dermatitis, via the acquisition of a wholly owned subsidiary of Numab Therapeutics.
May 29, 2024
The partnership will create therapeutic assets and new discovery platforms and potentially reshape drug discovery.
An ordered process describing calculations activities for compounded dosage forms is described.
May 28, 2024
Joe Payne, Scorpius BioManufacturing, comments on the unique needs of today's biopharmaceutical companies looking to develop and manufacture small-volume, early-stage large molecules.